Treatment of cutaneous T-cell lymphoma: focus on vorinostat.
Dialogues in Dermatology, a monthly audio program from the American Academy of Dermatology, contains discussions between dermatologists on timely topics. Commentaries from Dialogues Editor-in-Chief Warren R. Heymann, MD, are provided after each discussion as a topic summary and are provided here as a special service to readers of the Journal of the American Academy of Dermatology.
Heymann
Warren R
WR
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D005221:Fatigue / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006877:Hydroxamic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D011655:Pulmonary Embolism / Q000139:chemically induced; D000077337:Vorinostat
D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D000077337:Vorinostat